AESTHETIC FOCUS

Rosacea is a common chronic inflammatory facial condition that can lead to significant facial disfigurement and emotional suffering. Classically it manifests with four broad clinical subtypes (erythematotelangiectatic rosacea (ETR); papulopustular rosacea (PPR), phymatous rosacea, ocular rosacea) [1-2] and different cutaneous symptoms, including persistent centrofacial erythema (background erythema), visible blood vessels (telangiectasias), inflammatory lesions (papules / pustules), oedema, rhinophyma and ocular symptoms. In clinical practice, different combinations of subtype / cutaneous symptoms (phenotypes) are often seen and therefore a classification based on phenotypes rather than subtypes has recently been suggested [3-5].

The diagnosis of rosacea is mostly clinical and generally easy, however, it may be difficult to assess the clinical features or severity grade for a correct diagnosis and optimal treatment.

New therapeutic topical options for rosacea include brimonidine 0.33% gel and ivermectin (IVM) 1% cream which are able to control persistent erythema in ETR and inflammation in PPR respectively. In particular, brimonidine tartrate is a highly selective α2-adrenergic receptor agonist characterised by a marked vasoconstriction effect [6] and ivermectin is a macrolide agent isolated from the fermentation of Streptomyces avermitilis with anti-inflammatory and anti-parasitic effects [7-8]. Therapeutic effectiveness of these current topical options is based generally on clinical observation of either reduction of persistent erythema or inflammation.

Non-invasive imaging systems, like the VISIA-CR™ system (Canfield Scientific Inc., Fairfield, NJ, USA), can be used to optimise treatment outcomes more precisely than simple clinical inspection or standard photography. In particular, this system is equipped with RBX™ technology (erythema-directed digital photography) which is able to highlight the red areas corresponding to increased vascular flare / inflammation in some facial inflammatory dermatoses including rosacea [9-10], acne [11] and seborrhoeic dermatitis [12-14].

The aim of this article is to investigate whether erythema-directed digital photography may enhance the clinical evaluation in rosacea patients so as to identify the most appropriate treatment for both ETR and PPR.

How to facilitate treatment decision-making in a group of ETR patients with both background erythema and telangiectasias?

Erythematotelangiectatic rosacea is characterised by flushing (transient erythema), persistent centrofacial erythema (background erythema), and telangiectasias. The severity of individual symptoms differs in each patient and this may complicate the selection of a targeted treatment. Treatment decisions should be made based on the severity of individual symptoms. We have previously

Using erythema-directed digital photography in patients with rosacea

BY FEDERICA DALL’OGLIO, FRANCESCO LACARRUBBA AND GIUSEPPE MICALI

The authors, from the University of Catania in Italy, discuss the promise that erythema-directed digital photography is showing in the clinical evaluation and targeted treatment of rosacea.
establishing either an accurate rosacea grading score at baseline or patients under treatment with IVM 1% cream? Is it possible to enhance the clinical evaluation of PPR • Predominant telangiectasias with minimal background erythema • Background erythema associated with marked telangiectasias • Persistent erythema characterised mainly by background erythema and reduction of some telangiectasias (scenario one, excellent response).

Patient two (Figure 2) was a 60-year-old Caucasian female affected by ETR with both marked background erythema and telangiectasias for 20 years. She had been unresponsive to conventional rosacea treatment. Erythema-directed photography of the patient after six hours of application of brimonidine 0.33% gel showed marked improvement of background erythema and persistence of telangiectasias (scenario two, good improvement).

Patient three (Figure 3) was a 53-year-old Caucasian female affected by ETR with minimal background erythema and marked telangiectasias for 25 years. She had been unresponsive to conventional rosacea treatment. Erythema-directed photography of the patient after six hours of application of brimonidine 0.33% gel showed minimal reduction of background erythema and persistence of telangiectasias (scenario three, poor response to treatment).

Suggested management in ETR patients based on preliminary erythema-directed photography evaluation of the vascular component

Based on these erythema-directed photography findings, we suggest a targeted rosacea management as follows:

- Persistent erythema characterised mainly by background erythema (scenario one) is best managed by topical brimonidine.
- Background erythema associated with marked telangiectasias (scenario two) by a combined approach of topical brimonidine and vascular laser (Figure 4).
- Predominant telangiectasias with minimal background erythema (scenario three) by vascular laser only [10].

Is it possible to enhance the clinical evaluation of PPR patients under treatment with IVM 1% cream? In clinical practice, simple clinical observation does not allow for establishing either an accurate rosacea grading score at baseline or a correct post-treatment efficacy and tolerability evaluation. One study has evaluated the use of erythema-directed photography to enhance the evaluation of severity grading and therapeutic monitoring in a group of PPR patients [15]. Twenty patients with mild/ moderate PPR were instructed to apply IVM 1% cream for eight weeks. Clinical efficacy was evaluated by 1) Investigator Severity Assessment (ISA) at baseline (T0), at two (T1), four (T2), six (T3), and eight (T4) weeks using a five-point scale (0=clear; no erythema, no papules / pustules; 1=almost clear: very mild erythema, very few small papules / pustules; 2=mild: mild erythema, few small papules / pustules; 3=moderate: moderate erythema, several small or large papules / pustules; 4=severe: severe erythema, numerous small and / or large papules / pustules), and by 2) Investigator Global Assessment (IGA) of efficacy at week eight using a six-point scale: (−1=worsening; 0=no response; 1=mild response; <50% improvement; 2=moderate: 50-80% improvement; 3=excellent: >80% improvement; 4=complete response / clear). Instrumental evaluation of erythema was evaluated by erythema-directed digital photography at all time points by a five-point scale (0=no erythema; 1=very mild erythema; 2=mild erythema; 3=moderate erythema; 4=severe erythema). Data was analysed using the paired sample t-test (SPSS software). Nineteen patients (16 female / 3 male; mean age: 46.9 years) completed the study. One patient dropped out for local skin reactions. The results showed that at baseline no differences from ISA (mean value: 2.7±0.5) and erythema-directed digital photography (mean value: 2.7±0.5) mean values were found. After two weeks of treatment, no clinical difference was found at ISA (mean from 2.7±0.5 at baseline to 2.7±0.5 at two weeks) whereas a significant decrease of erythema was detected by erythema-directed digital photography (mean from 2.7±0.5 at baseline to 2.4±0.7; p=0.02). At four, six and eight weeks, a significant reduction of rosacea severity was observed at ISA (mean from 2.7±0.5 at baseline to 2.0±0.9 at four weeks, to 1.5±1.1 at six weeks, to 1.1±1.1 at eight weeks; p<0.001) correlating with a significant decrease of erythema degree by digital photography (mean from 2.7±0.5 at baseline to 2.0±0.9 at four weeks, to 1.6±1.2 at six weeks, to 1.1±1.1 at eight weeks; p<0.001) (Figure 5). IGA at eight weeks showed complete response in six cases (31.6%), excellent in five (26.3%), moderate in three (15.8%), mild in three (15.8%), and no change in two cases (10.5%). The study confirmed the efficacy of IVM 1% cream leading to complete response in 31.6% of patients at eight weeks and highlights the value of erythema-directed photography allowing clinicians to see changes not visible with the naked eye as early as week two.

Figure 4: Scenario two: Clinical (A1-D1) and erythema-directed photography (A2-D2) of a patient affected by ETR presenting at baseline with marked background erythema and marked telangiectasias (A1-A2). Moderate response six hours after topical application of brimonidine 0.33% gel, with reduction of the background erythema but persistence of telangiectasias (B1-B2). One month after one session of Nd:YAG laser, disappearance of most of the telangiectasias (C1-C2). Further topical application of brimonidine after 6 hours determined marked reduction of background erythema (D1-D2).

5. Van Zuuren EJ. Rosacea.

References


